Financial Lp Hrt Purchases 64,047 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt purchased 64,047 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider owned 126,993 shares in the company, valued at $191,759.43. This trade represents a 101.75% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20.

Bluejay Diagnostics Price Performance

NASDAQ:BJDX traded down $0.23 during mid-day trading on Monday, reaching $1.22. The stock had a trading volume of 973,437 shares, compared to its average volume of 1,803,857. The stock has a 50-day simple moving average of $2.69 and a two-hundred day simple moving average of $2.49. The stock has a market capitalization of $1.26 million, a PE ratio of -0.10 and a beta of 0.88. Bluejay Diagnostics, Inc. has a 12 month low of $1.03 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.